Jung Kim, Ph.D.
NCI Shady Grove
Jung Kim joined the Clinical Genetics Branch (CGB) as a postdoctoral fellow in 2016, was promoted to research fellow in 2019, and was appointed staff scientist in 2021. Dr. Kim earned her Ph.D. in cancer biology from the Driskill Graduate Program in Life Sciences at Northwestern University, Chicago, Illinois, in 2015, after which she completed a one-year T-32 NRSA postdoctoral fellowship in the Division of Hematology and Oncology. Her doctoral and postdoctoral research focused on the transcriptional regulation of key signaling pathways in prostate cancer, including miRNA and epigenetic regulators.
Dr. Kim works with Douglas Stewart, M.D., senior investigator, to understand the germline genetics of cancer susceptibility genes and associated pathways using the genome-first approach, especially focusing on DICER1 and associated miRNA processing genes, and to analyze somatic genomic data of DICER1-associated malignancies.
She is the co-developer of the Automated Germline Variant Pathogencity (AutoGVP) tool.